Burrage Capital Management LLC - Q2 2020 holdings

$143 Million is the total value of Burrage Capital Management LLC's 26 reported holdings in Q2 2020. The portfolio turnover from Q1 2020 to Q2 2020 was - .

 Value Shares↓ Weighting
ADCT NewADC THERAPEUTICS SA SHS ISIN#CH0499880968$6,315,000134,912
+100.0%
4.42%
FULC NewFULCRUM THERAPEUTICS INC COM$5,334,000291,645
+100.0%
3.73%
MRUS NewMERUS B V COM ISIN#NL0011606264$2,255,000140,176
+100.0%
1.58%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2020-08-14
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
EPIZYME INC COM7Q2 202115.9%
NeoGenomics Inc7Q2 20218.7%
OrthoPediatrics Corp7Q2 20217.3%
Y-MABS THERAPEUTICS INC COM7Q2 20214.3%
CRINETICS PHARMACEUTICALS INC COM7Q2 20215.6%
G1 THERAPEUTICS INC COM7Q2 20217.3%
PTC THERAPEUTICS INC COM6Q1 20218.0%
CYTOKINETICS INC COM NEW6Q2 20214.9%
TURNING PT THERAPEUTICS INC COM6Q2 20216.7%
APELLIS PHARMACEUTICALS INC COM6Q1 20213.5%

View Burrage Capital Management LLC's complete holdings history.

Latest significant ownerships (13-D/G)
Burrage Capital Management LLC Q2 2020 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
Protalix BioTherapeutics, Inc.Sold outJuly 30, 202100.0%
IVERIC bio, Inc.February 14, 2020103.4%

View Burrage Capital Management LLC's complete significant-ownership history.

Latest filings
TypeFiled
13F-HR2021-11-15
13F-HR2021-08-16
SC 13G/A2021-07-30
13F-HR2021-05-17
13F-HR2021-02-12
SC 13G2021-02-12
13F-HR2020-11-13
13F-HR2020-08-14
13F-HR2020-05-14
13F-HR2020-02-14

View Burrage Capital Management LLC's complete filings history.

Compare quarters

Export Burrage Capital Management LLC's holdings